Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review

Paolo A. Ascierto, Helen J. Gogas, Jean Jacques Grob, Salvador Martín Algarra, Peter Mohr, Johan Hansson, Axel Hauschild

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Interferon alfa (IFNα) and pegylated IFNα2b (PegIFNα2b) are the only agents currently approved for the adjuvant treatment of resected melanoma at high risk of recurrence. Meta-analyses showed statistically significant disease-free survival (DFS) and overall survival (OS) benefits versus controls but did not clarify optimal dose/duration. We review data from all recent clinical trials to provide the latest information on dose, duration, and potential predictive factors of treatment success. Recent data largely confirm DFS and OS benefits but optimal dose/duration is not clarified. The data suggest greater responses in patients with stage III micro-metastatic versus macro-metastatic disease, and ulceration may also predict greater sensitivity to therapy, although further investigation is needed. Presently, IFNα and PegIFNα2b remain valid adjuvant therapies following resection of high-risk melanoma; the most appropriate treatment regimen should be determined on an individual patient basis according to patient lifestyle and approach, potential for toxicity, and the available clinical evidence.

Original languageEnglish
Pages (from-to)149-161
Number of pages13
JournalCritical Reviews in Oncology/Hematology
Volume85
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Interferon-alpha
Melanoma
Disease-Free Survival
Therapeutics
Survival
Meta-Analysis
Life Style
Clinical Trials
Recurrence

Keywords

  • Adjuvant
  • Disease-free survival
  • Immunomodulation
  • Interferon alfa-2a
  • Interferon alfa-2b
  • Malignant melanoma
  • Peginterferon alfa-2b
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Adjuvant interferon alfa in malignant melanoma : An interdisciplinary and multinational expert review. / Ascierto, Paolo A.; Gogas, Helen J.; Grob, Jean Jacques; Algarra, Salvador Martín; Mohr, Peter; Hansson, Johan; Hauschild, Axel.

In: Critical Reviews in Oncology/Hematology, Vol. 85, No. 2, 02.2013, p. 149-161.

Research output: Contribution to journalArticle

Ascierto, Paolo A. ; Gogas, Helen J. ; Grob, Jean Jacques ; Algarra, Salvador Martín ; Mohr, Peter ; Hansson, Johan ; Hauschild, Axel. / Adjuvant interferon alfa in malignant melanoma : An interdisciplinary and multinational expert review. In: Critical Reviews in Oncology/Hematology. 2013 ; Vol. 85, No. 2. pp. 149-161.
@article{63dc6c7a7eb543eea8c90eceb7e00e6a,
title = "Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review",
abstract = "Interferon alfa (IFNα) and pegylated IFNα2b (PegIFNα2b) are the only agents currently approved for the adjuvant treatment of resected melanoma at high risk of recurrence. Meta-analyses showed statistically significant disease-free survival (DFS) and overall survival (OS) benefits versus controls but did not clarify optimal dose/duration. We review data from all recent clinical trials to provide the latest information on dose, duration, and potential predictive factors of treatment success. Recent data largely confirm DFS and OS benefits but optimal dose/duration is not clarified. The data suggest greater responses in patients with stage III micro-metastatic versus macro-metastatic disease, and ulceration may also predict greater sensitivity to therapy, although further investigation is needed. Presently, IFNα and PegIFNα2b remain valid adjuvant therapies following resection of high-risk melanoma; the most appropriate treatment regimen should be determined on an individual patient basis according to patient lifestyle and approach, potential for toxicity, and the available clinical evidence.",
keywords = "Adjuvant, Disease-free survival, Immunomodulation, Interferon alfa-2a, Interferon alfa-2b, Malignant melanoma, Peginterferon alfa-2b, Survival",
author = "Ascierto, {Paolo A.} and Gogas, {Helen J.} and Grob, {Jean Jacques} and Algarra, {Salvador Mart{\'i}n} and Peter Mohr and Johan Hansson and Axel Hauschild",
year = "2013",
month = "2",
doi = "10.1016/j.critrevonc.2012.07.004",
language = "English",
volume = "85",
pages = "149--161",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Adjuvant interferon alfa in malignant melanoma

T2 - An interdisciplinary and multinational expert review

AU - Ascierto, Paolo A.

AU - Gogas, Helen J.

AU - Grob, Jean Jacques

AU - Algarra, Salvador Martín

AU - Mohr, Peter

AU - Hansson, Johan

AU - Hauschild, Axel

PY - 2013/2

Y1 - 2013/2

N2 - Interferon alfa (IFNα) and pegylated IFNα2b (PegIFNα2b) are the only agents currently approved for the adjuvant treatment of resected melanoma at high risk of recurrence. Meta-analyses showed statistically significant disease-free survival (DFS) and overall survival (OS) benefits versus controls but did not clarify optimal dose/duration. We review data from all recent clinical trials to provide the latest information on dose, duration, and potential predictive factors of treatment success. Recent data largely confirm DFS and OS benefits but optimal dose/duration is not clarified. The data suggest greater responses in patients with stage III micro-metastatic versus macro-metastatic disease, and ulceration may also predict greater sensitivity to therapy, although further investigation is needed. Presently, IFNα and PegIFNα2b remain valid adjuvant therapies following resection of high-risk melanoma; the most appropriate treatment regimen should be determined on an individual patient basis according to patient lifestyle and approach, potential for toxicity, and the available clinical evidence.

AB - Interferon alfa (IFNα) and pegylated IFNα2b (PegIFNα2b) are the only agents currently approved for the adjuvant treatment of resected melanoma at high risk of recurrence. Meta-analyses showed statistically significant disease-free survival (DFS) and overall survival (OS) benefits versus controls but did not clarify optimal dose/duration. We review data from all recent clinical trials to provide the latest information on dose, duration, and potential predictive factors of treatment success. Recent data largely confirm DFS and OS benefits but optimal dose/duration is not clarified. The data suggest greater responses in patients with stage III micro-metastatic versus macro-metastatic disease, and ulceration may also predict greater sensitivity to therapy, although further investigation is needed. Presently, IFNα and PegIFNα2b remain valid adjuvant therapies following resection of high-risk melanoma; the most appropriate treatment regimen should be determined on an individual patient basis according to patient lifestyle and approach, potential for toxicity, and the available clinical evidence.

KW - Adjuvant

KW - Disease-free survival

KW - Immunomodulation

KW - Interferon alfa-2a

KW - Interferon alfa-2b

KW - Malignant melanoma

KW - Peginterferon alfa-2b

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84872614316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872614316&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2012.07.004

DO - 10.1016/j.critrevonc.2012.07.004

M3 - Article

C2 - 22874771

AN - SCOPUS:84872614316

VL - 85

SP - 149

EP - 161

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -